CD274 and triple-negative breast carcinoma: Taken together, these results suggest that GATA3-AS1 could be used in clinical practice as a biomarker that would form a part of targeted therapy strategies for PD-L1 positive tumors in triple negative breast cancer, for which pertuzumab, atezolizumab, and nab-paclitaxel are implemented as treatments [19].